Targeted anticancer potential against glioma cells of thymoquinone delivered by mesoporous silica core-shell nanoformulations with pH-dependent release

References

• Ostrom QT, Gittleman H, Farah P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro-Oncology. 2013;15(Suppl 2):ii1–ii56. doi:10.1093/neuonc/not15124137015
   PubMed Web of Science ®Google Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507. doi:10.1056/NEJMra070812618669428
   PubMed Web of Science ®Google Scholar
• Arko L, Katsyv I, Park GE, Luan WP, Park JK. Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther. 2010;128(1):1–36. doi:10.1016/j.pharmthera.2010.04.01520546782
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van Den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996. doi:10.1056/NEJMoa04333015758009
   PubMed Web of Science ®Google Scholar
• Hou LC, Veeravagu A, Hsu AR, Tse VC. Recurrent glioblastoma multiforme: a review of natural history and management options. Neurosurg Focus. 2006;20(4):E5. doi:10.3171/foc.2006.20.4.2
   PubMedGoogle Scholar
• Kim SS, Harford JB, Pirollo KF, Chang EH. Effective treatment of glioblastoma requires crossing the blood-brain barrier and targeting tumors including cancer stem cells: the promise of nanomedicine. Biochem Biophys Res Commun. 2015;468(3):485–489. doi:10.1016/j.bbrc.2015.06.13726116770
   PubMed Web of Science ®Google Scholar
• Nicholas MK, Lukas R, Bangalore S. Chemotherapy for malignant glioma. Expert Rev Neurother. 2005;5(6 Suppl):S41–S49. doi:10.1586/14737175.5.6.S4116274270
   PubMedGoogle Scholar
• Perry J, Laperriere N, Zuraw L, Chambers A, Spithoff K, Cairncross JG. Adjuvant chemotherapy for adults with malignant glioma: a systematic review. Can J Neurol Sci. 2007;34(4):402–410.18062446
   PubMed Web of Science ®Google Scholar
• Schneider-Stock R, Fakhoury IH, Zaki AM, El-Baba CO, Gali-Muhtasib HU. Thymoquinone: fifty years of success in the battle against cancer models. Drug Discov Today. 2014;19(1):18–30. doi:10.1016/j.drudis.2013.08.02124001594
   PubMed Web of Science ®Google Scholar
• Goyal SN, Prajapati CP, Gore PR, et al. Therapeutic potential and pharmaceutical development of thymoquinone: a multitargeted molecule of natural origin. Front Pharmacol. 2017;8:656. doi:10.3389/fphar.2017.0065628983249
   PubMed Web of Science ®Google Scholar
• Gali-Muhtasib H, Ocker M, Kuester D, et al. Thymoquinone reduces mouse colon tumor cell invasion and inhibits tumor growth in murine colon cancer models. J Cell Mol Med. 2008;12(1):330–342. doi:10.1111/j.1582-4934.2007.00095.x18366456
   PubMed Web of Science ®Google Scholar
• Jafri SH, Glass J, Shi R, Zhang S, Prince M, Kleiner-Hancock H. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: in vitro and in vivo. J Exp Clin Cancer Res. 2010;29:87. doi:10.1186/1756-9966-29-8720594324
   PubMed Web of Science ®Google Scholar
• El-Mahdy MA, Zhu Q, Wang QE, Wani G, Wani AA. Thymoquinone induces apoptosis through activation of caspase-8 and mitochondrial events in p53-null myeloblastic leukemia HL-60 cells. Int J Cancer. 2005;117(3):409–417. doi:10.1002/ijc.2120515906362
   PubMed Web of Science ®Google Scholar
• Arafa El SA, Zhu Q, Shah ZI, et al. Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. Mutat Res. 2011;706(1–2):28–35. doi:10.1016/j.mrfmmm.2010.10.00721040738
   PubMedGoogle Scholar
• Asaduzzaman Khan M, Tania M, Fu S, Fu J. Thymoquinone, as an anticancer molecule: from basic research to clinical investigation. Oncotarget. 2017;8(31):51907–51919. doi:10.18632/oncotarget.1720628881699
   PubMedGoogle Scholar
• Gurung RL, Lim SN, Khaw AK, et al. Thymoquinone induces telomere shortening, DNA damage and apoptosis in human glioblastoma cells. PLoS One. 2010;5(8):e12124. doi:10.1371/journal.pone.001212420711342
   PubMedGoogle Scholar
• Kolli-Bouhafs K, Boukhari A, Abusnina A, et al. Thymoquinone reduces migration and invasion of human glioblastoma cells associated with FAK, MMP-2 and MMP-9 down-regulation. Invest New Drugs. 2012;30(6):2121–2131. doi:10.1007/s10637-011-9777-322170088
   PubMed Web of Science ®Google Scholar
• Racoma IO, Meisen WH, Wang QE, Kaur B, Wani AA. Thymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cells. PLoS One. 2013;8(9):e72882. doi:10.1371/journal.pone.007288224039814
   PubMedGoogle Scholar
• Pazhouhi M, Sariri R, Rabzia A, Khazaei M. Thymoquinone synergistically potentiates temozolomide cytotoxicity through the inhibition of autophagy in U87MG cell line. Iran J Basic Med Sci. 2016;19(8):890–898.27746872
   PubMed Web of Science ®Google Scholar
• Elmaci I, Altinoz MA. Thymoquinone: an edible redox-active quinone for the pharmacotherapy of neurodegenerative conditions and glial brain tumors. A short review. Biomed Pharmacother. 2016;83:635–640. doi:10.1016/j.biopha.2016.07.01827459120
   PubMed Web of Science ®Google Scholar
• Chowdhury FA, Hossain MK, Mostofa AGM, Akbor MM, Bin Sayeed MS. Therapeutic potential of thymoquinone in glioblastoma treatment: targeting major gliomagenesis signaling pathways. Biomed Res Int. 2018;2018:4010629. doi:10.1155/2018/401062929651429
   PubMedGoogle Scholar
• Jakaria M, Cho D-Y, Ezazul Haque M, et al. Neuropharmacological potential and delivery prospects of thymoquinone for neurological disorders. Oxid Med Cell Longev. 2018;2018:17. doi:10.1155/2018/1209801
   Web of Science ®Google Scholar
• Banerjee I, De K, Mukherjee D, et al. Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced anti-angiogenic and anti-glioma therapy. Acta Biomater. 2016;38:69–81. doi:10.1016/j.actbio.2016.04.02627109765
   PubMed Web of Science ®Google Scholar
• Orunoğlu M, Kaffashi A, Pehlivan SB, et al. Effects of curcumin-loaded PLGA nanoparticles on the RG2 rat glioma model. Mater Sci Eng C. 2017;78:32–38. doi:10.1016/j.msec.2017.03.292
   PubMed Web of Science ®Google Scholar
• Lee ES, Gao Z, Bae YH. Recent progress in tumor pH targeting nanotechnology. J Controlled Release. 2008;132(3):164–170. doi:10.1016/j.jconrel.2008.05.003
   PubMed Web of Science ®Google Scholar
• Liu J, Huang Y, Kumar A, et al. pH-Sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv. 2014;32(4):693–710. doi:10.1016/j.biotechadv.2013.11.00924309541
   PubMed Web of Science ®Google Scholar
• Wirries A, Breyer S, Quint K, Schobert R, Ocker M. Thymoquinone hydrazone derivatives cause cell cycle arrest in p53-competent colorectal cancer cells. Exp Ther Med. 2010;1(2):369–375. doi:10.3892/etm_0000005822993551
   PubMed Web of Science ®Google Scholar
• Odeh F, Ismail SI, Abu-Dahab R, Mahmoud IS, Al Bawab A. Thymoquinone in liposomes: a study of loading efficiency and biological activity towards breast cancer. Drug Deliv. 2012;19(8):371–377. doi:10.3109/10717544.2012.72750023043626
   PubMed Web of Science ®Google Scholar
• Ng WK, Saiful Yazan L, Yap LH, Wan Nor Hafiza WAG, How CW, Abdullah R. Thymoquinone-loaded nanostructured lipid carrier exhibited cytotoxicity towards breast cancer cell lines (MDA-MB-231 and MCF-7) and cervical cancer cell lines (HeLa and SiHa). Biomed Res Int. 2015;2015:10. doi:10.1155/2015/263131
   Web of Science ®Google Scholar
• Dehghani H, Hashemi M, Entezari M, Mohsenifar A. The comparison of anticancer activity of thymoquinone and nanothymoquinone on human breast adenocarcinoma. IJPR. 2015;14(2):539–546.25901162
   PubMedGoogle Scholar
• Vallet-Regi M, Rámila A, Del Real RP, Pérez-Pariente J. A new property of MCM-41: drug delivery system. Chem Mater. 2001;13(2):308–311. doi:10.1021/cm0011559
   Web of Science ®Google Scholar
• Kwon S, Singh RK, Perez RA, Abou Neel EA, Kim H-W, Chrzanowski W. Silica-based mesoporous nanoparticles for controlled drug delivery. J Tissue Eng. 2013;4:2041731413503357. doi:10.1177/204173141350335724020012
   PubMedGoogle Scholar
• Wang Y, Zhao Q, Han N, et al. Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomedicine. 2015;11(2):313–327. doi:10.1016/j.nano.2014.09.01425461284
   PubMed Web of Science ®Google Scholar
• Watermann A, Brieger J. Mesoporous silica nanoparticles as drug delivery vehicles in cancer. Nanomaterials (Basel, Switzerland). 2017;7(7). doi:10.3390/nano7120458
   PubMedGoogle Scholar
• Baghirov H, Karaman D, Viitala T, et al. Feasibility study of the permeability and uptake of mesoporous silica nanoparticles across the blood-brain barrier. PLoS One. 2016;11(8):e0160705. doi:10.1371/journal.pone.016070527547955
   PubMed Web of Science ®Google Scholar
• Tamba BI, Streinu V, Foltea G, et al. Tailored surface silica nanoparticles for blood-brain barrier penetration: preparation and in vivo investigation. Arab J Chem. 2018;11(6):981–990. doi:10.1016/j.arabjc.2018.03.019
   Web of Science ®Google Scholar
• Shi J, Hou S, Huang J, et al. An MSN-PEG-IP drug delivery system and IL13Rα2 as targeted therapy for glioma. Nanoscale. 2017;9(26):8970–8981. doi:10.1039/c6nr08786h28443896
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang W, Zhou Y, Jiang Y, Li S. Dual functional mesoporous silicon nanoparticles enhance the radiosensitivity of VPA in glioblastoma. Transl Oncol. 2017;10(2):229–240. doi:10.1016/j.tranon.2016.12.01128193559
   PubMed Web of Science ®Google Scholar
• You Y, Yang L, He L, Chen T. Tailored mesoporous silica nanosystem with enhanced permeability of the blood–brain barrier to antagonize glioblastoma. J Mat Chem B. 2016;4(36):5980–5990. doi:10.1039/C6TB01329E
   PubMed Web of Science ®Google Scholar
• Mo J, He L, Ma B, Chen T. Tailoring particle size of mesoporous silica nanosystem to antagonize glioblastoma and overcome blood–brain barrier. ACS Appl Mater Interfaces. 2016;8(11):6811–6825. doi:10.1021/acsami.5b1173026911360
   PubMedGoogle Scholar
• Song Y, Du D, Li L, Xu J, Dutta P, Lin Y. In vitro study of receptor-mediated silica nanoparticles delivery across blood-brain barrier. ACS Appl Mater Interfaces. 2017;9(24):20410–20416. doi:10.1021/acsami.7b0350428541655
   PubMedGoogle Scholar
• Salmani JM, Asghar S, Lv H, Zhou J. Aqueous solubility and degradation kinetics of the phytochemical anticancer thymoquinone; probing the effects of solvents, pH and light. Molecules. 2014;19(5):5925–5939. doi:10.3390/molecules1905592524815311
   PubMed Web of Science ®Google Scholar
• El-Toni AM, Khan A, Ibrahim MA, et al. Synthesis of double mesoporous core-shell silica spheres with tunable core porosity and their drug release and cancer cell apoptosis properties. J Colloid Interface Sci. 2012;378(1):83–92. doi:10.1016/j.jcis.2012.04.00622551476
   PubMedGoogle Scholar
• Shen D, Yang J, Li X, et al. Biphase stratification approach to three-dimensional dendritic biodegradable mesoporous silica nanospheres. Nano Lett. 2014;14(2):923–932. doi:10.1021/nl404316v24467566
   PubMed Web of Science ®Google Scholar
• Hu F-Q, Zhao M-D, Yuan H, You J, Du Y-Z, Zeng S. A novel chitosan oligosaccharide–stearic acid micelles for gene delivery: properties and in vitro transfection studies. Int J Pharm. 2006;315(1):158–166. doi:10.1016/j.ijpharm.2006.02.02616632285
   PubMedGoogle Scholar
• Yuan H, Bao X, Du Y-Z, You J, Hu F-Q. Preparation and evaluation of SiO2-deposited stearic acid-g-chitosan nanoparticles for doxorubicin delivery. Int J Nanomedicine. 2012;7:5119–5128. doi:10.2147/IJN.S3557523055724
   PubMed Web of Science ®Google Scholar
• Yang T-S, Liu -T-T, Lin IH. Functionalities of chitosan conjugated with stearic acid and gallic acid and application of the modified chitosan in stabilizing labile aroma compounds in an oil-in-water emulsion. Food Chem. 2017;228:541–549. doi:10.1016/j.foodchem.2017.02.03528317761
   PubMed Web of Science ®Google Scholar
• Klein M, Aserin A, Ben Ishai P, Garti N. Interactions between whey protein isolate and gum Arabic. Colloids Surf B. 2010;79(2):377–383. doi:10.1016/j.colsurfb.2010.04.021
   PubMed Web of Science ®Google Scholar
• Franz TJ. Percutaneous absorption on the relevance of in vitro data. J Invest Dermatol. 1975;64(3):190–195.123263
   PubMed Web of Science ®Google Scholar
• Salama RO, Traini D, Chan HK, Young PM. Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols. Eur J Pharm Biopharm. 2008;70(1):145–152. doi:10.1016/j.ejpb.2008.04.00918534832
   PubMed Web of Science ®Google Scholar
• Ammar HO, Ghorab MM, Mahmoud AA, Higazy IM. Lamotrigine loaded poly-varepsilon-(d,l-lactide-co-caprolactone) nanoparticles as brain delivery system. Eur J Pharm Sci. 2018;115:77–87. doi:10.1016/j.ejps.2018.01.02829341900
   PubMed Web of Science ®Google Scholar
• Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1–2):55–63.6606682
   PubMed Web of Science ®Google Scholar
• Yergeau E, Arbour M, Brousseau R, et al. Microarray and real-time PCR analyses of the responses of high-arctic soil bacteria to hydrocarbon pollution and bioremediation treatments. Appl Environ Microbiol. 2009;75(19):6258–6267. doi:10.1128/AEM.01029-0919684169
   PubMedGoogle Scholar
• Qu F, Zhu G, Huang S, et al. Controlled release of Captopril by regulating the pore size and morphology of ordered mesoporous silica. Microporous Mesoporous Mater. 2006;92(1–3):1–9. doi:10.1016/j.micromeso.2005.12.004
   Web of Science ®Google Scholar
• AbouAitah K, Farghali A, Swiderska-Sroda A, Lojkowski W, Razin A, Khedr M. pH-controlled release system for curcumin based on functionalized dendritic mesoporous silica nanoparticles. J Nanomed Nanotechnol. 2016;7:1. doi:10.4172/2157-7439.1000351
   Google Scholar
• AbouAitah K, Farghali A, Swiderska-Sroda A, Lojkowski W, Razin A. Mesoporous silica materials in drug delivery system: pH/glutathione-responsive release of poorly water-soluble pro-drug quercetin from two and three-dimensional pore-structure nanoparticles. J Nanomed Nanotechnol. 2016;7:1. doi:10.4172/2157-7439.1000360
   Google Scholar
• Sahoo B, Devi KSP, Sahu SK, et al. Facile preparation of multifunctional hollow silica nanoparticles and their cancer specific targeting effect. Biomater Sci. 2013;1(6):647–657. doi:10.1039/c3bm00007a
   PubMed Web of Science ®Google Scholar
• Möller K, Kobler J, Bein T. Colloidal suspensions of nanometer-sized mesoporous silica. Adv Funct Mater. 2007;17(4):605–612
   Web of Science ®Google Scholar
• Poudel BK, Soe ZC, Ruttala HB, et al. In situ fabrication of mesoporous silica-coated silver-gold hollow nanoshell for remotely controllable chemo-photothermal therapy via phase-change molecule as gatekeepers. Int J Pharm. 2018;548(1):92–103. doi:10.1016/j.ijpharm.2018.06.05629959089
   PubMed Web of Science ®Google Scholar
• Sun Y, Sun Y-L, Wang L, Ma J, Yang Y-W, Gao H. Nanoassembles constructed from mesoporous silica nanoparticles and surface-coated multilayer polyelectrolytes for controlled drug delivery. Microporous Mesoporous Mater. 2014;185:245–253. doi:10.1016/j.micromeso.2013.11.020
   Web of Science ®Google Scholar
• Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol. 1975;27(1):48–49.235616
   PubMed Web of Science ®Google Scholar
• Rinaki E, Dokoumetzidis A, Macheras P. The mean dissolution time depends on the dose/solubility ratio. Pharm Res. 2003;20(3):406–408.12669960
   PubMed Web of Science ®Google Scholar
• Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15(1):25–35. doi:10.1016/0378-5173(83)90064-9
   Web of Science ®Google Scholar
• Karasulu HY, Ertan G, Kose T. Modeling of theophylline release from different geometrical erodible tablets. Eur J Pharm Biopharm. 2000;49(2):177–182. doi:10.1016/S0939-6411(99)00082-X10704902
   PubMedGoogle Scholar
• Surekha R, Aishwarya V, Sumathi T. Thymoquinone loaded solid lipid nanoparticle: formulation, characterization and in-vitro cell viability assay. Int J Pharm Bio Sci. 2014;6:449–464.
   Google Scholar
• Ritger PL, Peppas NA. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Controlled Release. 1987;5(1):37–42. doi:10.1016/0168-3659(87)90035-6
   Google Scholar
• Wang C, Fu X, Yang L. Water-soluble chitosan nanoparticles as a novel carrier system for protein delivery. Chin Sci Bull. 2007;52(7):883–889. doi:10.1007/s11434-007-0127-y
   Google Scholar
• Barahuie F, Dorniani D, Saifullah B, et al. Sustained release of anticancer agent phytic acid from its chitosan-coated magnetic nanoparticles for drug-delivery system. Int J Nanomedicine. 2017;12:2361–2372. doi:10.2147/IJN.S12624528392693
   PubMedGoogle Scholar
• Williams PA, Phillips GO. 11 - Gum arabic In: Phillips GO, Williams PA, editors. Handbook of Hydrocolloids. 2nd ed. Cambridge: Woodhead Publishing; 2009:252–273.
   Google Scholar
• Cornelsen PA, Quintanilha RC, Vidotti M, Gorin PA, Simas-Tosin FF, Riegel-Vidotti IC. Native and structurally modified gum arabic: exploring the effect of the gum’s microstructure in obtaining electroactive nanoparticles. Carbohydr Polym. 2015;119:35–43. doi:10.1016/j.carbpol.2014.11.02025563942
   PubMedGoogle Scholar
• Gunasekaran S, Ko S, Xiao L. Use of whey proteins for encapsulation and controlled delivery applications. J Food Eng. 2007;83(1):31–40. doi:10.1016/j.jfoodeng.2006.11.001
   Web of Science ®Google Scholar
• Abu-Dahab R, Odeh F, Ismail SI, Azzam H, Al Bawab A. Preparation, characterization and antiproliferative activity of thymoquinone-β-cyclodextrin self assembling nanoparticles. Die Pharm-Int J Pharm Sci. 2013;68(12):939–944.
   Google Scholar
• Bhattacharya S, Ahir M, Patra P, et al. PEGylated-thymoquinone-nanoparticle mediated retardation of breast cancer cell migration by deregulation of cytoskeletal actin polymerization through miR-34a. Biomaterials. 2015;51:91–107. doi:10.1016/j.biomaterials.2015.01.00725771001
   PubMed Web of Science ®Google Scholar
• AbouAitah K, Swiderska-Sroda A, Farghali AA, et al. Folic acid-conjugated mesoporous silica particles as nanocarriers of natural prodrugs for cancer targeting and antioxidant action. Oncotarget. 2018;9(41):26466–26490. doi:10.18632/oncotarget.2547029899871
   PubMedGoogle Scholar
• Choi JY, Ramasamy T, Kim SY, et al. PEGylated lipid bilayer-supported mesoporous silica nanoparticle composite for synergistic co-delivery of axitinib and celastrol in multi-targeted cancer therapy. Acta Biomater. 2016;39:94–105. doi:10.1016/j.actbio.2016.05.01227163403
   PubMed Web of Science ®Google Scholar
• Park EJ, Chauhan AK, Min KJ, Park DC, Kwon TK. Thymoquinone induces apoptosis through downregulation of c-FLIP and Bcl-2 in renal carcinoma Caki cells. Oncol Rep. 2016;36(4):2261–2267. doi:10.3892/or.2016.501927573448
   PubMed Web of Science ®Google Scholar
• Zhang M, Du H, Huang Z, et al. Thymoquinone induces apoptosis in bladder cancer cell via endoplasmic reticulum stress-dependent mitochondrial pathway. Chem Biol Interact. 2018;292:65–75. doi:10.1016/j.cbi.2018.06.01329981725
   PubMed Web of Science ®Google Scholar
• Gali-Muhtasib H, Diab-Assaf M, Boltze C, et al. Thymoquinone extracted from black seed triggers apoptotic cell death in human colorectal cancer cells via a p53-dependent mechanism. Int J Oncol. 2004;25(4):857–866.15375533
   PubMed Web of Science ®Google Scholar
• Xu D, Ma Y, Zhao B, et al. Thymoquinone induces G2/M arrest, inactivates PI3K/Akt and nuclear factor-kappaB pathways in human cholangiocarcinomas both in vitro and in vivo. Oncol Rep. 2014;31(5):2063–2070. doi:10.3892/or.2014.305924603952
   PubMedGoogle Scholar
• Alhosin M, Ibrahim A, Boukhari A, et al. Anti-neoplastic agent thymoquinone induces degradation of alpha and beta tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts. Invest New Drugs. 2012;30(5):1813–1819. doi:10.1007/s10637-011-9734-121881916
   PubMedGoogle Scholar
• Paramasivam A, Sambantham S, Shabnam J, et al. Anti-cancer effects of thymoquinone in mouse neuroblastoma (Neuro-2a) cells through caspase-3 activation with down-regulation of XIAP. Toxicol Lett. 2012;213(2):151–159. doi:10.1016/j.toxlet.2012.06.01122732633
   PubMedGoogle Scholar
• Rajput S, Kumar BN, Dey KK, Pal I, Parekh A, Mandal M. Molecular targeting of Akt by thymoquinone promotes G(1) arrest through translation inhibition of cyclin D1 and induces apoptosis in breast cancer cells. Life Sci. 2013;93(21):783–790. doi:10.1016/j.lfs.2013.09.00924044882
   PubMed Web of Science ®Google Scholar
• Xie Y-T, Du Y-Z, Yuan H, Hu F-Q. Brain-targeting study of stearic acid-grafted chitosan micelle drug-delivery system. Int J Nanomedicine. 2012;7:3235–3244. doi:10.2147/IJN.S3270122802685
   PubMed Web of Science ®Google Scholar
• Ha H-K, Kim JW, Lee M-R, Jun W, Lee W-J. Cellular uptake and cytotoxicity of β-lactoglobulin nanoparticles: the effects of particle size and surface charge. Asian-Aust J Anim Sci. 2015;28(3):420–427. doi:10.5713/ajas.14.0761
   PubMed Web of Science ®Google Scholar
• Bounous G. Whey protein concentrate (WPC) and glutathione modulation in cancer treatment. Anticancer Res. 2000;20(6c):4785–4792.11205219
   PubMed Web of Science ®Google Scholar
• Traverso N, Ricciarelli R, Nitti M, et al. Role of glutathione in cancer progression and chemoresistance. Oxid Med Cell Longev. 2013;2013:10. doi:10.1155/2013/972913
   Web of Science ®Google Scholar
• Ramasamy T, Ruttala HB, Gupta B, et al. Smart chemistry-based nanosized drug delivery systems for systemic applications: a comprehensive review. J Controlled Release. 2017;258:226–253. doi:10.1016/j.jconrel.2017.04.043
   PubMed Web of Science ®Google Scholar